Exosens share rebounds to its 200-day moving average, supported by US defense
The Bordeaux-based optronic company posts another positive session in a virtually unchanged SBF 120, standing out in a directionless European market. The stock returns to its long-term moving average after several weeks of pressure, while the ECB's decision on rates next Thursday creates an uncertain backdrop for markets.
A contained rebound that brings the share back to its 200-day MA at €58.36
Exosens gains 1.74% to €58.45 in trading, ranking among the strongest gainers of the SBF 120 in an index evolving at equilibrium (+0.04%). Today's movement brings the share back to its 200-day MA at €58.36, with a gap of only +0.15%: this long-term threshold plays the role of immediate technical floor. Conversely, the price remains below the 50-day MA at €59.79 (gap of -2.24%) and the 20-day MA at €60.81 (gap of -3.88%), illustrating the accumulated pressure on the share since the beginning of summer.
The RSI at 43 remains in neutral territory, without a clear reversal signal in either direction. Monthly volatility at 13.44% reflects an amplitude of fluctuations still elevated for this share, consistent with a decline of 7.59% over the last month despite a gain of 59.48% over twelve months. The support identified at €55.20 and resistance at €66.80 delimit the range in which the share has been trading for several weeks.
Solid fundamentals and dynamic export commercial performance underpinning the investment case
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Beyond today's movement, the investment case remains supported by several factors. Upon publication of first-half 2026 results (July 28, 2026), Exosens displayed growth of 15.3% and record adjusted EBITDA margin of 33.0%, illustrating the strength of its positioning in defense optronic systems. On the commercial side, the first BiNOD order secured in late August by its Photonis Defense subsidiary from the U.S. Army, as part of the binocular night vision program, confirms the group's breakthrough in the American market.
Upon publication of Q1 2026 results (April 27, 2026), the company had identified strengthening defense demand and the rise of advanced optronic technologies as its main growth drivers. These elements fit within a context of persistent geopolitical tensions — Brent above 97 dollars, Middle East tensions, discussions over a ceasefire in Ukraine — which structurally support defense budgets in Europe and the United States. Analyst views on the share remain an element to incorporate into a complete reading of the investment case. The next technical level to monitor is the breakthrough of the 50-day MA at €59.79, which would condition a return of the share to a more favorable technical configuration.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
